Notification that dealings with genetically modified carnation lines have been included on the GMO Register.
Clinical trial with a genetically modified Bordetella pertussis for the prevention of whooping cough
Details of OGTR monitoring and compliance activities during the quarter ended 31 March 2021
The report describes the roles and responsibilities of the Gene Technology Regulator (Regulator) and the OGTR. It provides a picture of the OGTR’s performance over the past 12 months.
The report describes the roles and responsibilities of the Gene Technology Regulator (the Regulator) and the OGTR during 2016-17.
The report describes the roles and responsibilities of the Gene Technology Regulator (the Regulator) and the Office of the Gene Technology Regulator (OGTR) during 2018-19.
The report describes the roles and responsibilities of the Gene Technology Regulator (the Regulator) and the Office of the Gene Technology Regulator (OGTR) during 2019-20.
The purpose of this document is to inform researchers undertaking NLRDs about the Gene Technology Regulator’s (the Regulator’s) operational policy for considering requests to conduct NLRDs in alternate facilities, pursuant to regulation 13(2)(c).
This document provides guidance to licence holders/applicants on the OGTR’s policy in relation to licensing for commercial release1 of genetically modified (GM) plants produced by conventional breeding (‘stacking’) between different, separately licensed, plant genetically modified organisms (GMOs).
This document provides guidance to DIR licence holders and applicants on crops that may be grown during the post harvest monitoring period after field trials. Currently this advice is limited to field trials of GM brassica (Brassica napus, Brassica juncea) and GM cotton.